Metastatic Sites of Esophageal Adenocarcinoma
Esophageal adenocarcinoma most commonly metastasizes to abdominal lymph nodes (45%), liver (35%), lungs (20%), bone (9%), adrenal glands (5%), peritoneum (2%), and brain (2%). 1
Primary Metastatic Pattern
The metastatic distribution follows a predictable hierarchy based on a comprehensive review of 838 newly diagnosed esophageal cancer cases 1:
Most Common Sites (in descending order):
- Abdominal lymph nodes: 45% of all metastases
- Liver: 35%
- Lungs: 20%
- Cervical lymph nodes: 18%
- Bone: 9%
- Adrenal glands: 5%
- Peritoneum: 2%
- Brain: 2%
Critical Clinical Pattern
An important finding is that all patients with bone and brain metastases had concurrent metastatic disease in the abdomen and thorax 1. This means isolated bone or brain metastases without thoracoabdominal involvement are exceptionally rare, which has practical implications for staging workup.
Staging Workup Implications
Based on this metastatic pattern, evaluation for distant disease should focus on the thorax and abdomen unless specific clinical symptoms suggest other sites 1. This is why current guidelines recommend:
- CT chest and abdomen as standard staging 2
- PET-CT to identify otherwise undetected distant metastases 2, 3
- Diagnostic laparoscopy for adenocarcinomas of the gastroesophageal junction extending ≥2 cm beyond the GEJ with T3/T4 disease, as peritoneal metastases occur in approximately 15% of these patients 2, 3
The sensitivity for detecting peritoneal metastases is only 15% with ultrasound or CT, but increases to 70% with laparoscopy 2.
Uncommon but Documented Sites
While rare, case reports document metastases to unusual locations 4, 5, 6, 7, 8:
- Biliary tree (exceedingly rare) 4
- Skeletal muscle 5
- Ovaries and fallopian tubes 6
- Chest wall and ribs 7
- Skin and subcutaneous tissues 8
A systematic review found unexpected metastases distributed to: head and neck (42%), thoracic sites (17%), abdomen/pelvis (25%), extremities (9%), and multiple skin/muscle sites (7%) 8. However, these represent exceptional cases rather than typical patterns.
Clinical Caveat
At diagnosis, approximately 18% of esophageal cancer patients already have distant metastases 1. This underscores the aggressive nature of the disease and the importance of thorough initial staging before embarking on potentially morbid curative-intent therapy.
The metastatic pattern differs slightly between tumor locations—lower esophageal adenocarcinomas show higher rates of abdominal and paracardial lymph node involvement, which is why tumors extending into the gastric cardia warrant laparoscopic evaluation 2, 9.